Bristol Myers Squibb - U.S. Food and Drug Administration …
网页4 天之前 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
Bristol Myers wins US FDA approval for new type of schizophrenia drug
网页2 天之前 · (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug …
网页3 天之前 · The medication, to be sold under the name Cobenfy, gained Food and Drug Administration clearance Thursday to treat patients with the illness that often produces hallucinations and delusions.
FDA approves Bristol Myers Squibb's schizophrenia drug
网页4 天之前 · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more...
Bristol Myers Squibb - U.S. Food and Drug Administration …
网页2024年5月6日 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo ® (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
网页2023年11月15日 · U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
US FDA approves Bristol Myers' schizophrenia drug | Reuters
网页3 天之前 · The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
A new kind of drug for schizophrenia promises fewer side effects
网页2 天之前 · For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by Bristol Myers Squibb will be called Cobenfy , though it had been …
FDA Approves Drug with New Mechanism of Action for Treatment …
网页4 天之前 · Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
U.S. Food and Drug Administration Approves Bristol Myers …
网页2 天之前 · PRINCETON, N.J., September 27, 2024 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and...